Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + erlotinib + imatinib
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A three-drug anticancer regimen combining the VEGF-A–neutralizing monoclonal antibody bevacizumab, the EGFR tyrosine kinase inhibitor erlotinib, and the PDGFR/KIT/BCR-ABL tyrosine kinase inhibitor imatinib. The rationale was simultaneous inhibition of tumor angiogenesis (VEGF/PDGFR signaling) and tumor cell proliferation/survival (EGFR signaling). In phase I/II studies in metastatic clear cell renal cell carcinoma, the regimen was found tolerable at bevacizumab 10 mg/kg IV every 2 weeks, erlotinib 150 mg PO daily, and imatinib 400 mg PO daily in dose-finding; however, in a larger cohort it produced substantial added toxicity without clear efficacy improvement over bevacizumab + erlotinib, leading investigators to recommend against further development of this triplet in RCC.[1][3][7]
- Other names
- bevacizumab erlotinib imatinib
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on bevacizumab + erlotinib + imatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + erlotinib + imatinib.